Major Cardiac Societies Redefine Heart Failure for the Modern Era

Heart failure affects tens of millions of people globally and its prevalence is climbing. Despite its enormous burden, the definition of heart failure has long suffered from subjectivity and ambiguity, which has hampered research, surveillance, and prevention efforts. The 2021 Universal Definition was a first step toward standardization, but rapid advances in the field demanded an update.

This 2026 expert consensus document, developed jointly by the American Heart Association, American College of Cardiology, European Society of Cardiology, and World Heart Federation, presents the Second Universal Definition of Heart Failure. It draws on contributions from the Heart Failure Society of America, the HFA of the ESC, and the Japanese Heart Failure Society, representing a truly global collaborative effort.

A central change is the reclassification of heart failure phenotypes. Rather than relying on rigid left ventricular ejection fraction cutoffs, the new framework groups patients into three categories: reduced, preserved, and improved ejection fraction. This shift is designed to better capture the clinical reality that heart failure is a dynamic, evolving condition rather than a static diagnosis. The document also proposes a standardized universal classification of heart failure causes, a long-standing gap in the field.

Equally important, the document formally recognizes disease trajectories such as improvement, remission, and recovery — concepts increasingly supported by clinical evidence but lacking standardized definitions. It also explicitly addresses the role of social determinants of health and geographic disparities in heart failure risk and outcomes, acknowledging that access to care shapes prognosis as much as biology does.

For clinicians and longevity-focused practitioners, the practical implications are significant. Standardized staging and classification should sharpen risk stratification, facilitate earlier intervention at pre-heart failure (stage B) stages, and support more consistent global research. Caveats include reliance on abstract-level detail only and the inherent lag between guideline publication and real-world clinical adoption.